Decision and Details
United States Patent and Trademark OfficeUS patent allowance for “exon-humanized mice”
As part of its growth strategy for its CRO business, the company is introducing and conducting research and development on versatile disease-model mice that can be applied to nonclinical studies, in order to expand its lineup. It explains that this patent will strengthen the intellectual property base supporting its competitive advantage.
No impact on consolidated results for the fiscal year ending March 2027
| Item | Details |
|---|---|
| Matter Covered | US patent allowance for “exon-humanized mice” |
| Decision-Making Body | United States Patent and Trademark Office |
| Decision Date | 22 April 2026 (the date the patent allowance was received) |
| Quantity / scale | International patent application (PCT/JP2019/021894), Japanese Patent No. 7699749 |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending March 2027 |
| Reason | As part of its growth strategy for its CRO business, the company is introducing and conducting research and development on versatile disease-model mice that can be applied to nonclinical studies, in order to expand its lineup. It explains that this patent will strengthen the intellectual property base supporting its competitive advantage. |
| Related previous disclosures | “Patent for ‘Exon-Humanized Mice’ Granted in Japan,” dated 2 July 2025; “Patent for ‘Exon-Humanized Mice’ Granted in Europe,” dated 21 August 2025 |
| Future plans | The company will promptly disclose any matters that arise requiring disclosure. It will continue working to enhance its high-value-added drug discovery support services. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is working to expand its disease-model mouse lineup as part of its growth strategy for its CRO business. It explains that this patent will strengthen the intellectual property base supporting the business advantages of exon-humanized mice.